From a therapeutic point of view (Figure 3), considering that IL-33 induces the production of pro-inflammatory cytokines from cells that express ST2 cells and hematopoietic cells including ILC2s, mast cells, Th2 cells, eosinophils, basophils and dendritic cells, the potential use of IL-33-blocking agents may be a novel therapeutic strategy to treat allergic diseases and some conditions characterized by this inflammatory profile [36,79]. This evidence concerns the gene IL1RL1 and allergic disease.